Key Developments: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

23 Jan 2015
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Merck & Co Inc and Eli Lilly and Co enter collaboration agreement
Tuesday, 13 Jan 2015 08:00am EST 

Merck & Co Inc and Eli Lilly and Co:Say an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials.Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer (NSCLC). This study is currently enrolling.Lilly will conduct a multiple-arm Phase 1/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015.Lilly will conduct a Phase 1/2 study examining the combination of necitumumab with pembrolizumab in NSCLC.This study is anticipated to begin in 2015.  Full Article

Merck & Co Inc acquires OncoEthix
Thursday, 18 Dec 2014 07:30am EST 

Merck & Co Inc:Says it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development.Through the acquisition, Merck has gained an investigational, novel oral BET (bromodomain) inhibitor, OTX015, which is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors.Financial terms of the acquisition include an upfront payment of up to $110 mln to OncoEthix.Additional milestone payments of up to $265 mln are contingent upon certain clinical and regulatory events being achieved.  Full Article

Zymeworks Inc and Merck & Co Inc extend and expand bi-specific antibody therapeutics collaboration
Tuesday, 9 Dec 2014 05:00am EST 

Zymeworks Inc:Says extension of research collaboration with Merck, known as MSD outside U.S and Canada, that was originally said in Aug. 2011.In addition, Merck gains expanded access to Zymeworks' proprietary Azymetric platform for development of novel bi-specific antibody therapeutic candidates.Under terms of this agreement Zymeworks has granted Merck, through subsidiary, worldwide license to develop and commercialize bi-specific antibodies generated through use of Azymetric platform towards certain therapeutic targets.Both Zymeworks and Merck will progress bi-specific therapeutic antibody candidates in pre-clinical developments with Merck responsible for clinical development and commercialization.  Full Article

Merck & Co to acquire Cubist Pharmaceuticals for $102 per share in cash
Monday, 8 Dec 2014 07:00am EST 

Merck & Co Inc and Cubist Pharmaceuticals Inc:Says that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 pct premium to Cubist's average stock price for the most recent five trading days.Transaction has an equity valuation of $8.4 bln and will also include $1.1 bln in net debt (based on projected cash balances) and other considerations for a total transaction value of about $9.5 bln.  Full Article

Merck & Co Inc increases quarterly dividend
Tuesday, 25 Nov 2014 01:00pm EST 

Merck & Co Inc:Increases the company's quarterly dividend to $0.45 per outstanding share of the company's common stock, up $0.01 from $0.44 per outstanding share paid last quarter.Payment will be made on Jan. 8, 2015, to stockholders of record at the close of business on Dec. 15.  Full Article

Merck submits new drug application to Japanese Pharmaceuticals And Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for type 2 diabetes
Monday, 24 Nov 2014 08:00am EST 

Merck & Co Inc:Company has submitted new drug application for omarigliptin, its investigational once-weekly DPP-4 inhibitor for treatment of type 2 diabetes, to Japanese Pharmaceuticals and Medical Devices Agency (PMDA).The new drug application for omarigliptin is based on a comprehensive clinical development program in Japan.  Full Article

Merck & Co., Inc announces positive study investigating use of KEYTRUDA
Friday, 14 Nov 2014 10:00pm EST 

Merck & Co., Inc:Announces a pre-specified analysis of investigational data from a pivotal Phase 2 study (KEYNOTE-002) showed KEYTRUDA (pembrolizumab).Says the company's anti-PD-1 therapy, substantially improved the primary endpoint of progression-free survival, compared to chemotherapy (P<0.0001 for both comparisons) in patients with ipilimumab-refractory advanced melanoma (n=540).Says at six months, the PFS rates for KEYTRUDA were 34 percent at the 2 mg/kg dose (95% CI, 27-41) (n=180) and 38 percent at the 10 mg/kg dose (95% CI, 31-45) (n=181), compared to 16 percent for chemotherapy (95% CI, 10-22) (n=179).These findings, including pre-specified analyses of overall response rate (ORR), duration of response, safety and health-related quality of life (HRQoL).Says KEYTRUDA is indicated in the United States at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.Says this indication is approved under accelerated approval based on tumor response rate and durability of response.Says an improvement in survival or disease-related symptoms has not yet been established.Says continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.  Full Article

Merck & Co Inc narrows FY 2014 EPS guidance and lowers high end of prior FY 2014 revenue guidance range
Monday, 27 Oct 2014 07:00am EDT 

Merck & Co Inc:Narrows FY 2014 non-GAAP EPS range to be between $3.46-$3.50.Says the range excludes acquisition- and divestiture-related costs and costs related to restructuring programs, as well as certain other items.Expects FY 2014 GAAP EPS range to be between $4.06-$4.29.Anticipates FY 2014 revenues to be between $42.4-$42.8 bln.FY 2014 revenue of $42.5 bln and EPS of $3.47 - Thomson Reuters I/B/E/S.  Full Article

US FDA accepts for review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
Monday, 20 Oct 2014 08:00am EDT 

Merck & Co Inc and Sanofi Pasteur:Says the Biologics License Application (BLA) filed for the companies` investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB1, has been accepted for review by the U.S. Food and Drug Administration (FDA).Says data from a Phase III study for the investigational pediatric hexavalent vaccine were recently presented at IDWeek in Philadelphia.Says this phase III study, a randomized, open-label, active-comparator controlled clinical trial with more than 1,400 infants at multiple centers across the United States, evaluated the safety and immunogenicity of the investigational pediatric hexavalent vaccine versus licensed comparator vaccines.Says the partnership between Merck and Sanofi Pasteur draws upon both companies' experience in the development, manufacturing and marketing of individual and combination vaccines.Sanofi Pasteur, is the vaccines division of Sanofi.  Full Article

Merck & Co. Inc prices 2.5 billion euros debt offering
Monday, 6 Oct 2014 12:28pm EDT 

Merck & Co. Inc:Priced 2.5 billion euros public offering of three series of Euro-denominated senior unsecured notes.Notes include: 1.0 billion euros of 1.125 pct notes due Oct. 2021.1.0 billion euros of 1.875 pct notes due Oct. 2026.500 million euros of 2.500% notes due Oct. 2034.Intends to use all or substantial portion of net proceeds from offering of New Notes to purchase notes and debentures that are validly tendered in connection with tender offers launched by company for certain outstanding notes and debentures.If there are net proceeds remaining after tender offers, company intends to redeem in whole or in part, 4 pct Notes due 2015 and 6 pct Senior Notes due 2017.Any remaining net proceeds will be used for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.If net proceeds of offering for New Notes are insufficient to pay for all of notes and debentures acquired by company in the tender offers, company will fund any additional amounts from cash on hand, commercial paper borrowings or other amounts available to company.Offering is expected to close on Oct. 15.BNP Paribas, Deutsche Bank AG, London Branch and J.P. Morgan Securities plc are acting as active joint book-running managers for offering.Merrill Lynch International and The Royal Bank of Scotland plc are acting as passive joint book-running managers for offering.  Full Article

Europe recommends seven new medicines for approval

LONDON - Europe recommended seven new drugs for approval on Friday, including two antibiotics for skin infections and a new treatment option for HIV.

Search Stocks